Identifying Potential Candidate Hub Genes and Functionally Enriched Pathways in the Immune Responses to Quadrivalent Inactivated Influenza Vaccines in the Elderly Through Co-Expression Network Analysis

Front Immunol. 2020 Dec 4:11:603337. doi: 10.3389/fimmu.2020.603337. eCollection 2020.

Abstract

Insights into the potential candidate hub genes may facilitate the generation of safe and effective immunity against seasonal influenza as well as the development of personalized influenza vaccines for the elderly at high risk of influenza virus infection. This study aimed to identify the potential hub genes related to the immune induction process of the 2018/19 seasonal quadrivalent inactivated influenza vaccines (QIVs) in the elderly ≥60 years by using weighted gene co-expression network analysis (WGCNA). From 63 whole blood samples from16 elderly individuals, a total of 13,345 genes were obtained and divided into eight co-expression modules, with two modules being significantly correlated with vaccine-induced immune responses. After functional enrichment analysis, genes under GO terms of vaccine-associated immunity were used to construct the sub-network for identification and functional validation of hub genes. MCEMP1 and SPARC were confirmed as the hub genes with an obvious effect on QIVs-induced immunity. The MCEMP1 expression was shown to be negatively correlated with the QIVs-associated reactogenicity within 7 days after vaccination, which could be suppressed by the CXCL 8/IL-8 and exacerbated by the Granzyme-B cytotoxic mediator. Meanwhile, the SPARC expression was found to increase the immune responses to the QIVs and contribute to the persistence of protective humoral antibody titers. These two genes can be used to predict QIVs-induced adverse reaction, the intensity of immune responses, and the persistence of humoral antibody against influenza. This work has shed light on further research on the development of personalized QIVs with appropriate immune responses and long-lasting immunity against the forthcoming seasonal influenza.

Keywords: MCEMP1; SPARC; hub genes; quadrivalent inactivated influenza vaccines (QIVs); reactogenicity; weighted gene co-expression network analysis (WGCNA).

Publication types

  • Clinical Trial, Phase III
  • Equivalence Trial

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Antibodies, Viral / blood
  • Biomarkers / blood
  • China
  • Cytokines / blood
  • Double-Blind Method
  • Female
  • Gene Expression Regulation
  • Gene Regulatory Networks*
  • Humans
  • Immunity, Humoral / genetics*
  • Immunogenicity, Vaccine / genetics*
  • Influenza Vaccines / administration & dosage*
  • Influenza Vaccines / adverse effects
  • Influenza Vaccines / immunology
  • Influenza, Human / genetics
  • Influenza, Human / immunology
  • Influenza, Human / prevention & control*
  • Influenza, Human / virology
  • Male
  • Membrane Proteins / genetics
  • Middle Aged
  • Osteonectin / genetics
  • Time Factors
  • Transcriptome*
  • Vaccination

Substances

  • Antibodies, Viral
  • Biomarkers
  • Cytokines
  • Influenza Vaccines
  • MCEMP1 protein, human
  • Membrane Proteins
  • Osteonectin
  • SPARC protein, human